top of page
Check out the latest news from Ocelot Bio.
November 4, 2022
Ocelot Bio Presents Phase 1 Data Highlighting Activity and Safety of OCE-205 at AASLD The Liver Meeting
October 24, 2022
Ocelot Bio to Present Data Highlighting Pharmacodynamic Activity and Safety of OCE-205 at AASLD The Liver Meeting
August 22, 2022
Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Hepatorenal Syndrome
March 23, 2022
Patients can’t wait and neither will we.
Our passion for improving the lives of people with severe complications of liver disease is the foundation of our company.
bottom of page